Abstract：
:The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained that oral drug administration entails new and relevant management problems. Multiple studies have demonstrated the efficacy of imatinib in GISTs associated with a good toxicity profile. However, the efficacy of imatinib, according to its mechanism of action and pharmacokinetics, is closely related to daily assumption. No interruption or "jerky" assumption is permitted in order to avoid efficacy loss. Thus, the issue of treatment adherence is crucial for a successful strategy and should not be overlooked. We think that dealing with the problem means assessing a wide spectrum of not only clinical and general but also psychological and individual aspects. Furthermore, both patient and family should play an active role in the "cure process" and physicians should reduce the distance separating them from their patients due to home-based target therapy, promoting communication and consolidation of a trust-based physician-patient relationship. Several advantages have been introduced by oral target therapies in oncology. However, chronic drug administration, even if generally well tolerated, when prolonged for an undetermined time could heavily impact on patients' quality of life. This could induce non-prescribed drug suspension, with negative impact on disease control. More studies would be necessary in order to detect real patients' adherence, to correlate drug assumption with clinical outcome and to optimize imatinib treatment strategy.
journal_name
Target Oncoljournal_title
Targeted oncologyauthors
Saponara M,Pantaleo MA,Nannini M,Biasco Gdoi
10.1007/s11523-012-0221-1subject
Has Abstractpub_date
2012-12-01 00:00:00pages
243-6issue
4eissn
1776-2596issn
1776-260Xjournal_volume
7pub_type
杂志文章abstract：:Despite recent advances that have been made in the therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC), effective management of bone metastases remains a key goal not yet reached. The receptor tyrosine kinase MET and the vascular endothelial growth factor receptor (VEGFR) seem to play an i...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-015-0412-7
更新日期：2016-08-01 00:00:00
abstract：:The ubiquitin (Ub)+proteasome proteolytic pathway is responsible for the selective degradation of the majority of nuclear and cytosolic proteins. The proteasome is a high molecular weight multicatalytic protease that serves as the catalytic core of the complex Ub-dependent protein degradation pathway and is an excitin...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-010-0165-2
更新日期：2010-12-01 00:00:00
abstract：BACKGROUND:Cancer is a multifactorial disease, which makes it difficult to cure. Since more than one defective cellular component is often involved during oncogenesis, combination therapy is gaining prominence in the field of cancer therapeutics. OBJECTIVE:The purpose of this study was to investigate the combinatorial...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-016-0441-x
更新日期：2016-10-01 00:00:00
abstract：:Venetoclax (Venclyxto®; Venclexta®) is a first-in-class, oral, selective B cell lymphoma-2 (BCL-2) inhibitor. The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL); the specific indication(s)...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-019-00673-1
更新日期：2019-10-01 00:00:00
abstract：:Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the t...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-009-0104-2
更新日期：2009-01-01 00:00:00
abstract：:The influence of tumor infiltrating lymphocytes on tumor growth and response to therapy is becoming increasingly apparent. While much work has focused on the role of T cell responses in anti-tumor immunity, the role of B cells in solid tumors is much less understood. Tumor infiltrating B cells have been found in a var...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0481-x
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:Hypovitaminosis D is associated with an adverse prognosis in colon cancer patients, possibly due to the effects of the vitamin on the immune system. Antibody-dependent cell-mediated cytotoxicity (ADCC) significantly contributes to the anti-tumor effects of monoclonal antibodies, including cetuximab, an epide...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-018-0586-x
更新日期：2018-10-01 00:00:00
abstract：:The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00715-z
更新日期：2020-06-01 00:00:00
abstract：:Mesothelin is a tumor differentiation antigen, which is highly expressed in several solid neoplasms, including pancreatic cancer. Its selective expression on malignant cells and on only a limited number of healthy tissues has made it an interesting candidate for investigation as a diagnostic and prognostic biomarker a...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-018-0567-0
更新日期：2018-06-01 00:00:00
abstract：:Data regarding the expression of epidermal growth factor receptor (EGFR) in melanoma and its role in the tumor biology are conflicting. In BRAF V600-mutant melanomas, the expression of EGFR has been associated with acquired resistance to BRAF inhibitors. In this study, we assessed EGFR expression and downstream signal...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-014-0318-9
更新日期：2015-03-01 00:00:00
abstract：BACKGROUND:In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. OBJECTIVE:In this study, we investigated the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the outcomes of nivolumab monotherapy...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00716-y
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations. OBJECTIVE:The purpose of this study was to assess...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-017-0497-2
更新日期：2017-08-01 00:00:00
abstract：:Dynamic contrast-enhanced ultrasonography (DCE-US) is a new functional technique enabling a quantitative assessment of solid tumor perfusion using raw linear data. DCE-US allows the calculation of parameters as slope of wash-in or area under the curve (AUC) representing, respectively, blood flow or blood volume. Reduc...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-010-0136-7
更新日期：2010-03-01 00:00:00
abstract：:Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tu...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-012-0216-y
更新日期：2012-06-01 00:00:00
abstract：:In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-015-0361-1
更新日期：2015-12-01 00:00:00
abstract：:We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGFR-TKIs) for late relapsing (>5 years) metastatic renal cell carcinoma (mRCC). Data were collected fr...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-014-0356-3
更新日期：2015-12-01 00:00:00
abstract：:Basal transcription regulation of the epidermal growth factor receptor is dependent upon a CA simple sequence repeat polymorphism in the intron-1 (CA-SSR-1). Here, we evaluate the role of CA-SSR-1 in complete resected esophageal cancer (EC) patients without neoadjuvant or adjuvant treatment. Genomic DNA was extracted ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0260-2
更新日期：2014-03-01 00:00:00
abstract：BACKGROUND:The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions. OBJECTIVE:We assessed changes in programmed cell death-1 (PD1)/PD1 ligand (PDL1) expression in key immunomodulatory cell subsets (myeloid-derived suppressor ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-018-0595-9
更新日期：2018-10-01 00:00:00
abstract：:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall surviva...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0484-7
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE:As the distribution of PTCL subtypes differs between populations and few p...
journal_title：Targeted oncology
pub_type： 杂志文章,多中心研究
doi：10.1007/s11523-019-00630-y
更新日期：2019-04-01 00:00:00
abstract：:Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same bene...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-010-0163-4
更新日期：2010-12-01 00:00:00
abstract：:The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC marke...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0290-9
更新日期：2014-09-01 00:00:00
abstract：:In anticancer drug development, there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death. Irrespective of overt clinical toxicities, QTc assessmen...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-014-0325-x
更新日期：2015-03-01 00:00:00
abstract：BACKGROUND:The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE:This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients wi...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00701-5
更新日期：2020-02-01 00:00:00
abstract：:With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal tox...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-015-0368-7
更新日期：2015-12-01 00:00:00
abstract：:Hypoxia is a critical hallmark of solid tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma a...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-012-0233-x
更新日期：2012-12-01 00:00:00
abstract：BACKGROUND:A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). OBJECTIVE:Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-018-0599-5
更新日期：2018-12-01 00:00:00
abstract：:It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting th...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-009-0123-z
更新日期：2009-12-01 00:00:00
abstract：:Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-015-0384-7
更新日期：2016-04-01 00:00:00
abstract：:ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, Europ...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-019-00675-z
更新日期：2019-12-01 00:00:00
